{"id":56424,"date":"2026-02-05T20:49:13","date_gmt":"2026-02-05T12:49:13","guid":{"rendered":"https:\/\/flcube.com\/?p=56424"},"modified":"2026-02-05T20:49:14","modified_gmt":"2026-02-05T12:49:14","slug":"hanx-biopharma-hx111-adc-begins-phase-i-trial-for-lymphoma-and-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56424","title":{"rendered":"Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors"},"content":{"rendered":"\n

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.<\/strong> (HKG: 3378<\/a>) announced the initiation of a Phase I clinical trial<\/strong> for its self\u2011developed candidate HX111<\/strong>, an OX40\u2011targeting antibody\u2011drug conjugate (ADC)<\/strong>, in patients with relapsed or refractory lymphoma and solid tumors<\/strong>. HX111 is the first disclosed OX40\u2011targeting ADC worldwide to enter clinical stage.<\/p>\n\n\n\n

Regulatory Milestone & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK)<\/td><\/tr>
Drug<\/strong><\/td>HX111<\/td><\/tr>
Mechanism<\/strong><\/td>OX40\u2011targeting antibody\u2011drug conjugate (ADC)<\/td><\/tr>
Indication<\/strong><\/td>Relapsed or refractory lymphoma and solid tumors<\/td><\/tr>
Clinical Stage<\/strong><\/td>Phase I trial initiated<\/td><\/tr>
Innovation<\/strong><\/td>First disclosed OX40\u2011targeting ADC worldwide to enter clinical stage<\/td><\/tr>
Target<\/strong><\/td>OX40 molecules highly expressed on certain lymphomas and solid tumors<\/td><\/tr>
Mechanism of Action<\/strong><\/td>High\u2011affinity OX40 binding \u2192 endocytosis \u2192 lysosomal protease cleavage \u2192 payload release \u2192 tumor cell apoptosis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action & Clinical Rationale<\/h2>\n\n\n\n